Skip to Content

'
Vassiliki Papadimitrakopoulou, M.D.

Present Title & Affiliation

Primary Appointment

Associate Professor, Department of Thoracic Head and Neck Medical Oncology, Division of Cancer Medicine, UT M. D. Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

1988 University of Patras School of Medicine, Patras, Greece, MD, Medicine

Postgraduate Training

7/1994-6/1997 Clinical Fellowship, Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX
7/1991-6/1994 Clinical Residency, Internal Medicine, Columbia Presbyterian Medical Center, New York City
1/1990-6/1991 Clinical Residency, Institut Gustave Roussy, Unite La Grange, Savigny Le Temple, France
10/1988-11/1989 Clinical Internship, Metaxas Cancer Hospital, Piraeus, Greece

Board Certifications

1/1997 Internal Medicine, Medical Oncology
1/1994 Internal Medicine

Experience/Service

Academic Appointments

Assistant Professor, Department of Thoracic/Head & Neck Medical Oncology, Division of OVP, Cancer Prevention and Population Sciences, UT M. D. Anderson Cancer Center, Houston, TX, 10/1998-8/2003
Instructor, Department of Thoracic/Head & Neck Medical Oncology, Division of Cancer Medicine, UT M. D. Anderson Cancer Center, Houston, TX, 7/1997-8/1998

Selected Publications

Peer-Reviewed Original Research Articles
1. William WN, Lee JJ, Lippman SM, Martin JW, Train HT, Sabichi AL, Kim ES, Feng L, Papadimitrakopoulou V. High dose Fenretinide in oral leukoplakia. Cancer Prev Res (Phila Pa) 2(1):22-6, 1/2009. PMID: 19139014.
2. Blumenschein GR Jr, Kies MS, Papadimitrakopoulou VA, Lu C, Kumar AJ, Ricker JL, Chiao JH, Chen C, Frankel SR. Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinzatrade mark, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer. Invest New Drugs 26(1):81-7, 2008.
3. Papadimitrakopoulou V, William W Jr, Dannenberg A, Lippman S, Lee JL, Ondrey F, Peterson D, Feng L, Atwell A, El-Naggar A, Nathan C, Helman J, Du B, Yueh B, Boyle J. Pilot randomized Phase II study of celecoxib in oral premalignant lesions. Clin Cancer Res 14(7):2095-101, 2008. PMID: 18381950.
4. Kawaguchi H, El-Naggar AK, Papadimitrakopoulou V, Ren H, Fan YH, Feng L, Lee JJ, Kim E, Hong WK, Lippman SM, Mao L. Podoplanin: A novel marker for oral cancer risk in patients with oral premalignancy. J Clin Oncol 26:354-60, 2008.
5. Heymach JV, Nilsson M, Blumenschein G, Papadimitrakopoulou V, Herbst R.. Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer. Clin Cancer Res 12(14 Pt 2):441S-445S, 2006. PMID: 16857825.
6. Lippman SM. Lee JJ. Martin JW. El-Naggar AK. Xu X. Shin DM. Thomas M. Mao L. Fritsche HA Jr. Zhou X. Papadimitrakopoulou V. Khuri FR. Tran H. Clayman GL. Hittelman WN. Hong WK. Lotan R. Fenretinide activity in retinoid-resistant oral leukoplakia. [Clinical Trial, Phase II. Research Support, N.I.H., Extramural]. Clin Cancer Res 12:3109-14, 2006.
7. Gillenwater A. Papadimitrakopoulou V. Richards-Kortum R. Oral premalignancy: new methods of detection and treatment. Curr Oncol Reports:146-54, 2006.
8. Tsao AS, Garden AS, Kies MS, Morrison W, Feng L, Lee JJ, Khuri F, Zinner R, Myers J, Papadimitrakopoulou V, Lewin J, Clayman GL, Ang KK, Glisson BS. Phase I/II Study of Docetaxel, Cisplatin, and Concomitant Boost Radiation for Patients with locally Advanced Squamous Cell Cancer of the Head and Neck. J Clin Oncol 24:4163-9, 2006.
9. Papadimitrakopoulou, V, Adjei, AA. The Akt/mTOR and MAP Kinase Pathways in Lung Cancer Therapy. J Thor Oncol 1 (7):749-51, 2006.
10. Papadimitrakopoulou VA, Brown EN, Liu DD, El-Naggar AK, Lee JJ, Hong WK, and Lee HY.. The Prognostic Role of Loss of Insulin-like Growth Factor-binding Protein-3 Expression in Head and Neck Carcinogenesis. Cancer Lett 239(1):136-43, 2006. e-Pub 9/2005. PMID: 16181731.

Last updated: 9/8/2009